Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PARI GmbH
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
Five new OTC cough and cold products have hit the shelves in Germany this winter from Pari, Pohl Boskamp, Engelhard Arzneimittel, GSK and Dr Soldan.
The latest drug development news and highlights from our FDA Performance Tracker.
- Medical Devices
- Drug Delivery
- Site Specific
- Other Names / Subsidiaries
- PARI Medical Holding
- PARI Pharma GmbH
- PARltec GmbH
- PARI Worldwide, PARI Respiratory Equipment, Inc.